These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 15154658

  • 1. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
    Denschlag D, Watermann D, Hörig K, Kissel C, Tempfer C, Gitsch G.
    Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
    [Abstract] [Full Text] [Related]

  • 2. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG.
    Gynecol Oncol; 2006 Nov; 103(2):637-41. PubMed ID: 16781766
    [Abstract] [Full Text] [Related]

  • 3. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M, Rose PG.
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [Abstract] [Full Text] [Related]

  • 4. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.
    Gynecol Oncol; 2004 Dec; 95(3):686-90. PubMed ID: 15581982
    [Abstract] [Full Text] [Related]

  • 6. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T.
    Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 8. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
    Brown JV, Peters WA, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP.
    Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
    [Abstract] [Full Text] [Related]

  • 9. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 2000 Oct; 79(1):116-9. PubMed ID: 11006042
    [Abstract] [Full Text] [Related]

  • 10. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS, Blessing JA, Lentz SS, McMeekin DS.
    Cancer; 2003 Oct 15; 98(8):1664-9. PubMed ID: 14534883
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T.
    Gynecol Oncol; 2007 Apr 15; 105(1):205-10. PubMed ID: 17239430
    [Abstract] [Full Text] [Related]

  • 12. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P, Nolte S, Shahin MS.
    Gynecol Oncol; 2002 May 15; 85(2):278-84. PubMed ID: 11972388
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
    Markman M, Blessing JA, Alvarez RD, Hanjani P, Waggoner S, Hall K.
    Gynecol Oncol; 2000 Apr 15; 77(1):112-5. PubMed ID: 10739699
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 15; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.